Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2018

28.12.2016 | Original Research

An Alternative Method for Screening Gastric Cancer Based on Serum Levels of CEA, CA19-9, and CA72-4

verfasst von: Junxiu Yu, Wanlei Zheng

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The goal of this study was to create a novel method for screening gastric cancer (GC) based on serum levels of carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4) tumor markers.

Methods

Retrospectively, the predictive value for GC was calculated using a logistic analysis on serum levels of CEA, CA19-9, and CA72-4 from 216 GC and 49 benign patients. The predictive value was used to make a recommendation system on whether further GC screening was necessary. Prospectively, 80 GC and 33 benign patients were used to assess the value of this method.

Results

The recommendation system to determine whether additional GC screening was necessary consisted of three grades: grade I, no proposals; grade II, proposals; grade III, strong proposals. Additional screening was suggested when the predictive value was ≤0.700 (grade I), 0.700–0.850 (grade II), and >0.850 (grade III). Of the total 216 GC patients, 20.4, 27.8, and 51.9% were classified as grades I, II, and III, respectively. Of the 49 benign cases, 57.1, 32.7, and 10.2% were classified as grades I, II, and III, respectively. Of the 80 prospective GC patients, 17.3, 28.4, and 54.3% were classified as grades I, II, and III, respectively. Of the 33 prospective benign cases, 54.6, 33.3, and 12.1% were classified as grades I, II, and III, respectively.

Conclusion

The new screening recommendation system based on serum levels of CEA, CA19-9, and CA72-4 is an effective approach for detecting GC.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
3.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Handbook. New York: Springer; 2010. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Handbook. New York: Springer; 2010.
4.
Zurück zum Zitat Marrelli D, Pedrazzani C, Morgagni P, et al. Changing clinical and pathological features of gastric cancer over time. Br J Surg. 2011;98:1273–83.CrossRefPubMed Marrelli D, Pedrazzani C, Morgagni P, et al. Changing clinical and pathological features of gastric cancer over time. Br J Surg. 2011;98:1273–83.CrossRefPubMed
5.
Zurück zum Zitat Ding YB, Xia TS, Wu JD, et al. Surgical outcomes for gastric cancer of a single institute in southeast China. Am J Surg. 2012;203:217–21.CrossRefPubMed Ding YB, Xia TS, Wu JD, et al. Surgical outcomes for gastric cancer of a single institute in southeast China. Am J Surg. 2012;203:217–21.CrossRefPubMed
6.
Zurück zum Zitat Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1–27.CrossRefPubMed Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1–27.CrossRefPubMed
7.
Zurück zum Zitat Jeong O, Park YK. Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients. J Gastric Cancer. 2011;11:69–77.CrossRefPubMedPubMedCentral Jeong O, Park YK. Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients. J Gastric Cancer. 2011;11:69–77.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Lee S, Jun JK, Suh M, et al. Gastric cancer screening uptake trends in Korea: results for the national cancer screening program from 2002 to 2011: a prospective cross-sectional study. Medicine. 2015;94:e533.CrossRefPubMedPubMedCentral Lee S, Jun JK, Suh M, et al. Gastric cancer screening uptake trends in Korea: results for the national cancer screening program from 2002 to 2011: a prospective cross-sectional study. Medicine. 2015;94:e533.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Hamashima C, Ogoshi K, Narisawa R, et al. Impact of endoscopic screening on mortality reduction from gastric cancer. World J Gastroenterol. 2015;21:2460–6.CrossRefPubMedPubMedCentral Hamashima C, Ogoshi K, Narisawa R, et al. Impact of endoscopic screening on mortality reduction from gastric cancer. World J Gastroenterol. 2015;21:2460–6.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Choi KS, Jun JK, Lee HY, et al. Performance of gastric cancer screening by endoscopy testing through the National Cancer Screening Program of Korea. Cancer Sci. 2011;102:1559–64.CrossRefPubMed Choi KS, Jun JK, Lee HY, et al. Performance of gastric cancer screening by endoscopy testing through the National Cancer Screening Program of Korea. Cancer Sci. 2011;102:1559–64.CrossRefPubMed
11.
Zurück zum Zitat Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65:30–54.CrossRefPubMed Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65:30–54.CrossRefPubMed
12.
Zurück zum Zitat Kim DH, Oh SJ, Oh CA, et al. The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol. 2011;104:585–91.CrossRefPubMed Kim DH, Oh SJ, Oh CA, et al. The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol. 2011;104:585–91.CrossRefPubMed
13.
Zurück zum Zitat Kwon OK, Yu W, Chung H. Prognostic value of postoperative CA19-9 normalization in patients with advanced gastric cancer. Hepato-Gastroenterology. 2013;60:240–3.PubMed Kwon OK, Yu W, Chung H. Prognostic value of postoperative CA19-9 normalization in patients with advanced gastric cancer. Hepato-Gastroenterology. 2013;60:240–3.PubMed
14.
Zurück zum Zitat Jo JC, Ryu MH, Koo DH, et al. Serum CA 19-9 as a prognostic factor in patients with metastatic gastric cancer. Asia Pac J Clin Oncol. 2013;9:324–30.CrossRefPubMed Jo JC, Ryu MH, Koo DH, et al. Serum CA 19-9 as a prognostic factor in patients with metastatic gastric cancer. Asia Pac J Clin Oncol. 2013;9:324–30.CrossRefPubMed
15.
Zurück zum Zitat Choi AR, Park JC, Kim JH, et al. High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer. World J Gastroenterol. 2013;19:5302–8.CrossRefPubMedPubMedCentral Choi AR, Park JC, Kim JH, et al. High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer. World J Gastroenterol. 2013;19:5302–8.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Mohri Y, Tanaka K, Ohi M, et al. Identification of prognostic factors and surgical indications for metastatic gastric cancer. BMC Cancer. 2014;14:409.CrossRefPubMedPubMedCentral Mohri Y, Tanaka K, Ohi M, et al. Identification of prognostic factors and surgical indications for metastatic gastric cancer. BMC Cancer. 2014;14:409.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat He CZ, Zhang KH, Li Q, et al. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013;13:87.CrossRefPubMedPubMedCentral He CZ, Zhang KH, Li Q, et al. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013;13:87.CrossRefPubMedPubMedCentral
18.
19.
Zurück zum Zitat Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.CrossRefPubMed Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.CrossRefPubMed
20.
Zurück zum Zitat Bagaria B, Sood S, Sharma R, et al. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). Cancer Biol Med. 2013;10:148–57.PubMedPubMedCentral Bagaria B, Sood S, Sharma R, et al. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). Cancer Biol Med. 2013;10:148–57.PubMedPubMedCentral
21.
Zurück zum Zitat Leja M, You W, Camargo MC, et al. Implementation of gastric cancer screening—the global experience. Best Pract Res Clin Gastroenterol. 2014;28:1093–106.CrossRefPubMed Leja M, You W, Camargo MC, et al. Implementation of gastric cancer screening—the global experience. Best Pract Res Clin Gastroenterol. 2014;28:1093–106.CrossRefPubMed
22.
Zurück zum Zitat Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700–13.CrossRefPubMedPubMedCentral Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700–13.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Park CH, Kim EH, Jung DH, et al. The new modified ABCD method for gastric neoplasm screening. Gastric Cancer. 2016;19:128–35. Park CH, Kim EH, Jung DH, et al. The new modified ABCD method for gastric neoplasm screening. Gastric Cancer. 2016;19:128–35.
24.
Zurück zum Zitat Corso G, Pedrazzani C, Pinheiro H, et al. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer. 2011;47:631–9.CrossRefPubMed Corso G, Pedrazzani C, Pinheiro H, et al. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer. 2011;47:631–9.CrossRefPubMed
25.
26.
Zurück zum Zitat Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16:e60–70.CrossRefPubMed Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16:e60–70.CrossRefPubMed
27.
Zurück zum Zitat Gomceli I, Bostanci EB, Ozer I, et al. A novel screening biomarker in gastric cancer: serum Dickkopf-1. Hepato-Gastroenterology. 2012;59:1661–4.PubMed Gomceli I, Bostanci EB, Ozer I, et al. A novel screening biomarker in gastric cancer: serum Dickkopf-1. Hepato-Gastroenterology. 2012;59:1661–4.PubMed
28.
Zurück zum Zitat Cui L, Zhang X, Ye G, et al. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer. 2013;119:1618–26.CrossRefPubMed Cui L, Zhang X, Ye G, et al. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer. 2013;119:1618–26.CrossRefPubMed
29.
Zurück zum Zitat Leja M, Kupcinskas L, Funka K, et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci. 2011;56:145–50.CrossRefPubMed Leja M, Kupcinskas L, Funka K, et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci. 2011;56:145–50.CrossRefPubMed
30.
Zurück zum Zitat Murphy G, Kamangar F, Dawsey SM, et al. The relationship between serum ghrelin and the risk of gastric and esophagogastric junctional adenocarcinomas. J Natl Cancer Inst. 2011;103:1123–9.CrossRefPubMedPubMedCentral Murphy G, Kamangar F, Dawsey SM, et al. The relationship between serum ghrelin and the risk of gastric and esophagogastric junctional adenocarcinomas. J Natl Cancer Inst. 2011;103:1123–9.CrossRefPubMedPubMedCentral
Metadaten
Titel
An Alternative Method for Screening Gastric Cancer Based on Serum Levels of CEA, CA19-9, and CA72-4
verfasst von
Junxiu Yu
Wanlei Zheng
Publikationsdatum
28.12.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2018
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9912-7

Weitere Artikel der Ausgabe 1/2018

Journal of Gastrointestinal Cancer 1/2018 Zur Ausgabe

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.